Habitual abortion
Drug research and approvals for habitual abortion: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 14 studies of habitual abortion are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 14
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Efficacy of Recombinant Human G-CSF in Women With Unexplained Recurrent MiscarriageNCT07724405 · Phase 2 · Fakih IVF Fertility Center · starts Jul 10, 2026
- A Multicenter, Prospective, Randomized Controlled Clinical Study on the Effect of Hysteroscopic Uterine Septum…NCT07611656 · Not applicable · The Third Xiangya Hospital of Central South University · starts Jun 1, 2025
- Azithromycin for Cerclage ProphylaxisNCT07608562 · Phase 4 · Wake Forest University Health Sciences · starts Oct 15, 2026
- Immune Cell Populations in the EndometriumNCT06826365 · Not reported · Jagiellonian University · starts Jul 1, 2025
- Autologous Decidual-like Natural Killer Cells Therapy for Infertility or Adverse Pregnancy HistoryNCT06821685 · Phase 1 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · starts Feb 13, 2025
- Optimal Timing of Routine Cervical Length Measurements During Anatomy SurveyNCT06822647 · Not applicable · Henry Ford Health System · starts Jan 20, 2025
- Chronic Endometritis and Benefits of Antibiotics in Women With Recurrent MiscarriageNCT06163092 · Not reported · Chinese University of Hong Kong · starts Apr 1, 2024
- Nordic Randomized Trial on Laparoscopic Versus Vaginal CerclageNCT06122506 · Not applicable · University of Aarhus · starts Jan 31, 2024
- Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?NCT05969574 · Not reported · ART Fertility Clinics LLC · starts Sep 9, 2023
Phase 3 7
- AspirinCyclooxygenase inhibitor
- Dalteparin sodiumAntithrombin-III activator
- Enoxaparin sodiumAntithrombin-III activator
- Human immunoglobulin gReplacement therapy, immunomodulatory effects
- HydroxychloroquineFerriprotoporphyrin IX inhibitor
- DydrogesteroneProgesterone receptor agonist
- Albumin humanBilirubin sequestering agent
Phase 2 1
Phase 1 or earlier 2
- AldesleukinInterleukin-2 receptor agonist
- Soybean oil
How its trials ended
138 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 18 whose ending is known, 28% met their primary endpoint, 33% missed it and 39% stopped early.
- Completed, result not reported5641%
- Status unknown3727%
- Ongoing2720%
- Missed its primary endpoint64%
- Met its primary endpoint54%
- Stopped: other or unclear54%
- Stopped: enrollment or feasibility21%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA